

# Pharmacy Prior Authorization Form

Fax completed form to: 877.974.4411 toll free, or 616.942.8206

This form applies to:  Commercial (Traditional)  Commercial (Individual/Optimized)

Medicaid

This request is:  Urgent (life threatening)  Non-Urgent (standard review)

Urgent means the standard review time may seriously jeopardize the life or health of the patient or the patient's ability to regain maximum function.

## Xarelto<sup>®</sup> (rivaroxaban)

### Member

Last Name: \_\_\_\_\_

First Name: \_\_\_\_\_

ID #: \_\_\_\_\_

DOB: \_\_\_\_\_ Gender: \_\_\_\_\_

Primary Care Physician: \_\_\_\_\_

Requesting Provider: \_\_\_\_\_

Prov. Phone: \_\_\_\_\_ Prov. Fax: \_\_\_\_\_

Provider Address: \_\_\_\_\_

Provider NPI: \_\_\_\_\_

Contact Name: \_\_\_\_\_

Provider Signature: \_\_\_\_\_

Date: \_\_\_\_\_

### Product Information

New request  Continuation request

Drug product:  Xarelto 10mg  
 Xarelto 15mg  
 Xarelto 20mg

Start date (or date of next dose): \_\_\_\_\_

Date of last dose (if applicable): \_\_\_\_\_

Dosing frequency: \_\_\_\_\_

### Precertification Requirements

Before this drug is covered, the patient must meet all of the following requirements:

1. Patient was started on Xarelto therapy in the hospital and was discharged while on the therapy **OR**
2. Diagnosis of non-valvular atrial fibrillation (NVAf) at risk of stroke and systemic embolism, DVT prophylaxis in patients undergoing knee or hip replacement surgery, or for the treatment of DVT, pulmonary embolism (PE) and for the reduction in the risk of recurrence of DVT and PE.
  - a. Trial and failure of warfarin

**Note:** Authorization for indications, dosing, or a route of administration not approved by the Food and Drug Administration (FDA) or recognized in CMS-accepted compendia (e.g. DrugDex, AHFS, U.S. Pharmacopeia, and also Clinical Pharmacology for oncology indications only) require supporting evidence for coverage. Please provide two published peer-reviewed literature articles supporting the appropriateness of the drug, the dosing of the drug, or the route of administration to be used for the identified indication.

### Priority Health Precertification Documentation

**A. Patient was started on Xarelto therapy in the hospital and was discharged while on the therapy?**

- Yes  
 No: See next question.

**B. What condition is this drug being requested for?**

- Non-valvular atrial fibrillation with:  
 Treatment of DVT or PE  
 Prophylaxis of DVT  
 Prevention of recurrence of DVT or PE  
 Other: \_\_\_\_\_

**C. Has the patient had a trial and failure with warfarin?**

Yes Dates: \_\_\_\_\_

No: Rationale: \_\_\_\_\_

**D. For diagnosis of non-valvular atrial fibrillation only, which of the following apply to this patient?**

History of stroke, TIA, or systemic embolism

**OR** (must be at least two of the following)

Heart failure or LVEF  $\leq$  35%

Hypertension

$\geq$  75 years old

Diabetes mellitus

**E. For prophylaxis of DVT only, which of the following apply to this patient?**

Hip Replacement surgery (35 days recommended)

Knee Replacement surgery (12 days recommended)